Monitoring the Impact of National HPV vaccinaTion program in Japan (MINT study) -Following the Commencement of a Publicly Funded HPV Vaccine Project for Adolescent Females- (Period I: April 2012 - December 2019)

Monitoring the Impact of National HPV vaccinaTion program in Japan (MINT study) -Following the Commencement of a Publicly Funded HPV Vaccine Project for Adolescent Females- (Period I: April 2012 - December 2019) - Monitoring the Impact of National HPV vaccinaTion program in Japan (MINT study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008891

Enrollment

4000

Registered

2012-09-11

Start date

2012-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer and its precursor lesions

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All females, aged 16-39, who are newly diagnosed with cervical cancer, CIS or AIS and have not yet been treated.

Exclusion criteria

Exclusion criteria: Individuals in either of the groups listed below will be excluded as subjects of this research 1. Female patients younger than 16 or older than 39 2. Females who do not have CIN 1, CIN 2/3, AIS or cervical cancer

Design outcomes

Primary

Measure	Time frame
The proportion of HPV 16/18 positives among subjects of cervical cancer, grades 2/3 CIN (CIN 2/3) and AIS in women aged 16-25	—

Secondary

Measure	Time frame
1. The number of women aged 16-25 who contract cervical cancer, CIN 2/3, AIS 2. The proportion of HPV 16/18 positives among women aged 16-25 with CIN 1 3. The proportion of HPV 16/18 positives among subjects of cervical cancer, CIN 2/3 and AIS in women aged 16-39 4. The distribution of types of HPV among subjects of cervical cancer, CIN 1, CIN 2/3 and AIS in women aged 16-39 5. The number of women aged 16-39 who contract cervical cancer, CIN 2/3, AIS 6. The proportion of HPV 16/18 positives among women aged 16-39 with CIN 1 7. The number of deaths from cervical cancer among women aged 16-39	—

Measure

Time frame

1. The number of women aged 16-25 who contract cervical cancer, CIN 2/3, AIS 2. The proportion of HPV 16/18 positives among women aged 16-25 with CIN 1 3. The proportion of HPV 16/18 positives among subjects of cervical cancer, CIN 2/3 and AIS in women aged 16-39 4. The distribution of types of HPV among subjects of cervical cancer, CIN 1, CIN 2/3 and AIS in women aged 16-39 5. The number of women aged 16-39 who contract cervical cancer, CIN 2/3, AIS 6. The proportion of HPV 16/18 positives among women aged 16-39 with CIN 1 7. The number of deaths from cervical cancer among women aged 16-39

—

Countries

Japan

Contacts

Public ContactKoji Matsumoto

University of Tsukuba Department of Obstetrics and Gynecology, Faculty of Medicine

matsumok@md.tsukuba.ac.jp029-853-3073

Outcome results